{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:23:21Z","timestamp":1773102201882,"version":"3.50.1"},"reference-count":13,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,2,9]],"date-time":"2016-02-09T00:00:00Z","timestamp":1454976000000},"content-version":"vor","delay-in-days":404,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1016\/j.jaad.2014.08.050","type":"journal-article","created":{"date-parts":[[2014,9,26]],"date-time":"2014-09-26T18:41:04Z","timestamp":1411756864000},"page":"115-122","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":66,"title":["OBSERVE-5: Observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results"],"prefix":"10.1016","volume":"72","author":[{"given":"Alexa B.","family":"Kimball","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth J.","family":"Rothman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory","family":"Kricorian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Pariser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul S.","family":"Yamauchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9314-0007","authenticated-orcid":false,"given":"Alan","family":"Menter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig F.","family":"Teller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Girish","family":"Aras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil A.","family":"Accortt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Hooper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kara Creamer","family":"Rice","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joel M.","family":"Gelfand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2014.08.050_bib1","series-title":"Enbrel (etanercept) [prescribing information]","year":"2013"},{"key":"10.1016\/j.jaad.2014.08.050_bib2","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1016\/j.jaad.2010.07.026","article-title":"Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult population","volume":"66","author":"Papp","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2014.08.050_bib3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/247553031016a00301","article-title":"OBSERVE-5, an observational post-marketing safety surveillance registry of etanercept for the treatment of psoriasis: a simple model for studying new psoriasis therapies","volume":"16","author":"Kimball","year":"2010","journal-title":"Psoriasis Forum"},{"key":"10.1016\/j.jaad.2014.08.050_bib4","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.jaad.2012.10.055","article-title":"OBSERVE-5 interim analysis: an observational postmarketing safety registry of etanercept for the treatment of psoriasis","volume":"68","author":"Kimball","year":"2013","journal-title":"J Am Acad Dermatol"},{"issue":"Suppl","key":"10.1016\/j.jaad.2014.08.050_bib5","doi-asserted-by":"crossref","first-page":"ii65","DOI":"10.1136\/ard.2004.031237","article-title":"Psoriasis assessment tools in clinical trials","volume":"64","author":"Feldman","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2014.08.050_bib6","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index (DLQI)\u2013a simple practical measure for routine clinical use","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2014.08.050_bib7","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1001\/archdermatol.2012.370","article-title":"Comparative effectiveness of commonly used systemic treatments or phototherapy for moderate to severe plaque psoriasis in the clinical practice setting","volume":"148","author":"Gelfand","year":"2012","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2014.08.050_bib8","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jaad.2011.07.040","article-title":"Integrated safety analysis: short- and long-term safety profiles of etanercept in patients with psoriasis","volume":"67","author":"Pariser","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2014.08.050_bib9","first-page":"289","article-title":"Clinical trial safety and mortality analyses in patients receiving etanercept across approved indications","volume":"10","author":"Gottlieb","year":"2011","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaad.2014.08.050_bib10","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.jaad.2010.09.734","article-title":"The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials","volume":"64","author":"Dommasch","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2014.08.050_bib11","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1177\/120347541201600305","article-title":"Biologic therapy in psoriasis: perspectives on associated risks and patient management","volume":"16","author":"Papp","year":"2012","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.jaad.2014.08.050_bib12","first-page":"778","article-title":"The risk of malignancy associated with psoriasis","volume":"137","author":"Margolis","year":"2001","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2014.08.050_bib13","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1038\/sj.jid.5700410","article-title":"The risk of lymphoma in patients with psoriasis","volume":"126","author":"Gelfand","year":"2006","journal-title":"J Invest Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962214019094?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962214019094?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:33:29Z","timestamp":1759271609000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962214019094"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["S0190962214019094"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2014.08.050","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718892236.793500434","asserted-by":"object"}]},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2015,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"OBSERVE-5: Observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2014.08.050","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 American Academy of Dermatology, Inc. Published by Mosby, Inc.","name":"copyright","label":"Copyright"}]}}